1
|
Atlas N, Uzair B, Movellan J, Gracia R, Dupin D, Loinaz I, van Nostrum CF, Hays JP. In vitro activity of novel apramycin-dextran nanoparticles and free apramycin against selected Dutch and Pakistani Klebsiella pneumonia isolates. Heliyon 2023; 9:e22821. [PMID: 38125473 PMCID: PMC10730580 DOI: 10.1016/j.heliyon.2023.e22821] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2023] [Revised: 11/20/2023] [Accepted: 11/20/2023] [Indexed: 12/23/2023] Open
Abstract
Klebsiella pneumoniae are bacteria associated with respiratory tract infections and are increasingly becoming resistant to antibiotics, including carbapenems. Apramycin is a veterinary antibiotic that may have the potential to be re-purposed for use in human health, for example, for the treatment of respiratory tract infections after coupling to inhalable nanoparticles. In the present study, the antibiotic apramycin was formulated with single chain polymeric nanoparticles and tested in free and formulated forms against a set of 13 Klebsiella pneumoniae isolates (from the Netherlands and Pakistan) expressing different aminoglycoside resistance phenotypes. Minimum Inhibitory Concentration, Time Kill Kinetics and biofilm experiments were performed providing evidence for the potential efficacy of apramycin and apramycin-based nanomedicines for the treatment of human Klebsiella pneumonia infections.
Collapse
Affiliation(s)
- Nagina Atlas
- Dept. Biological Science, International Islamic University Islamabad, Pakistan
- Utrecht Institute for Pharmaceutical Sciences, Dept. of Pharmaceutics, Utrecht University, Utrecht, the Netherlands
| | - Bushra Uzair
- Dept. Biological Science, International Islamic University Islamabad, Pakistan
| | - Julie Movellan
- CIDETEC, Basque Research and Technology Alliance (BRTA), Parque Científico y Tecnológico de Gipuzkoa, Miramon Pasealekua, 196, Donostia-San Sebastián 20014, Spain
| | - Raquel Gracia
- CIDETEC, Basque Research and Technology Alliance (BRTA), Parque Científico y Tecnológico de Gipuzkoa, Miramon Pasealekua, 196, Donostia-San Sebastián 20014, Spain
| | - Damien Dupin
- CIDETEC, Basque Research and Technology Alliance (BRTA), Parque Científico y Tecnológico de Gipuzkoa, Miramon Pasealekua, 196, Donostia-San Sebastián 20014, Spain
| | - Iraida Loinaz
- CIDETEC, Basque Research and Technology Alliance (BRTA), Parque Científico y Tecnológico de Gipuzkoa, Miramon Pasealekua, 196, Donostia-San Sebastián 20014, Spain
| | - Cornelus F. van Nostrum
- Utrecht Institute for Pharmaceutical Sciences, Dept. of Pharmaceutics, Utrecht University, Utrecht, the Netherlands
| | - John P. Hays
- Dept. Medical Microbiology & Infectious Diseases, Erasmus University Medical Centre (Erasmus MC), Rotterdam, the Netherlands
| |
Collapse
|
2
|
Vicente-Ruiz S, Armiñán A, Maso K, Gallon E, Zagorodko O, Movellan J, Rodríguez-Otormín F, Baues M, May JN, De Lorenzi F, Lammers T, Vicent MJ. Poly-l-glutamic acid modification modulates the bio-nano interface of a therapeutic anti-IGF-1R antibody in prostate cancer. Biomaterials 2023; 301:122280. [PMID: 37598440 DOI: 10.1016/j.biomaterials.2023.122280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2023] [Revised: 08/04/2023] [Accepted: 08/12/2023] [Indexed: 08/22/2023]
Abstract
Modifying biological agents with polymers such as polyethylene glycol (PEG) has demonstrated clinical benefits; however, post-market surveillance of PEGylated derivatives has revealed PEG-associated toxicity issues, prompting the search for alternatives. We explore how conjugating a poly-l-glutamic acid (PGA) to an anti-insulin growth factor 1 receptor antibody (AVE1642) modulates the bio-nano interface and anti-tumor activity in preclinical prostate cancer models. Native and PGA-modified AVE1642 display similar anti-tumor activity in vitro; however, AVE1642 prompts IGF-1R internalization while PGA conjugation prompts higher affinity IGF-1R binding, thereby inhibiting IGF-1R internalization and altering cell trafficking. AVE1642 attenuates phosphoinositide 3-kinase signaling, while PGA-AVE1642 inhibits phosphoinositide 3-kinase and mitogen-activated protein kinase signaling. PGA conjugation also enhances AVE1642's anti-tumor activity in an orthotopic prostate cancer mouse model, while PGA-AVE1642 induces more significant suppression of cancer cell proliferation/angiogenesis than AVE1642. These findings demonstrate that PGA conjugation modulates an antibody's bio-nano interface, mechanism of action, and therapeutic activity.
Collapse
Affiliation(s)
- Sonia Vicente-Ruiz
- Polymer Therapeutics Laboratory, Prince Felipe Research Center (CIPF), 46012, Valencia, Spain
| | - Ana Armiñán
- Polymer Therapeutics Laboratory, Prince Felipe Research Center (CIPF), 46012, Valencia, Spain; CIBERONC, Instituto de Salud Carlos III, 28029, Madrid, Spain.
| | - Katia Maso
- Polymer Therapeutics Laboratory, Prince Felipe Research Center (CIPF), 46012, Valencia, Spain
| | - Elena Gallon
- Polymer Therapeutics Laboratory, Prince Felipe Research Center (CIPF), 46012, Valencia, Spain
| | - Oleksandr Zagorodko
- Polymer Therapeutics Laboratory, Prince Felipe Research Center (CIPF), 46012, Valencia, Spain
| | - Julie Movellan
- Polymer Therapeutics Laboratory, Prince Felipe Research Center (CIPF), 46012, Valencia, Spain; Current address: CIDETEC, Basque Research and Technology Alliance (BRTA), Parque Científico y Tecnológico de Gipuzkoa, Donostia-San Sebastián, Spain
| | | | - Maike Baues
- Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging (ExMI), RWTH Aachen University Clinic, Aachen, 52074, Germany
| | - Jan-Niklas May
- Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging (ExMI), RWTH Aachen University Clinic, Aachen, 52074, Germany
| | - Federica De Lorenzi
- Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging (ExMI), RWTH Aachen University Clinic, Aachen, 52074, Germany
| | - Twan Lammers
- Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging (ExMI), RWTH Aachen University Clinic, Aachen, 52074, Germany
| | - María J Vicent
- Polymer Therapeutics Laboratory, Prince Felipe Research Center (CIPF), 46012, Valencia, Spain; CIBERONC, Instituto de Salud Carlos III, 28029, Madrid, Spain.
| |
Collapse
|
3
|
Fernández Y, Movellan J, Foradada L, Giménez V, García‐Aranda N, Mancilla S, Armiñán A, Borgos SE, Hyldbakk A, Bogdanska A, Gobbo OL, Prina‐Mello A, Ponti J, Calzolai L, Zagorodko O, Gallon E, Niño‐Pariente A, Paul A, Schwartz Jr S, Abasolo I, Vicent MJ. In Vivo Antitumor and Antimetastatic Efficacy of a Polyacetal-Based Paclitaxel Conjugate for Prostate Cancer Therapy. Adv Healthc Mater 2022; 11:e2101544. [PMID: 34706167 DOI: 10.1002/adhm.202101544] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2021] [Revised: 09/25/2021] [Indexed: 12/12/2022]
Abstract
Prostate cancer (PCa), one of the leading causes of cancer-related deaths, currently lacks effective treatment for advanced-stage disease. Paclitaxel (PTX) is a highly active chemotherapeutic drug and the first-line treatment for PCa; however, conventional PTX formulation causes severe hypersensitivity reactions and limits PTX use at high concentrations. In the pursuit of high molecular weight, biodegradable, and pH-responsive polymeric carriers, one conjugates PTX to a polyacetal-based nanocarrier to yield a tert-Ser-PTX polyacetal conjugate. tert-Ser-PTX conjugate provides sustained release of PTX over 2 weeks in a pH-responsive manner while also obtaining a degree of epimerization of PTX to 7-epi-PTX. Serum proteins stabilize tert-Ser-PTX, with enhanced stability in human serum versus PBS (pH 7.4). In vitro efficacy assessments in PCa cells demonstrate IC50 values above those for the free form of PTX due to the differential cell trafficking modes; however, in vivo tolerability assays demonstrate that tert-Ser-PTX significantly reduces the systemic toxicities associated with free PTX treatment. tert-Ser-PTX also effectively inhibits primary tumor growth and hematologic, lymphatic, and coelomic dissemination, as confirmed by in vivo and ex vivo bioluminescence imaging and histopathological evaluations in mice carrying orthotopic LNCaP tumors. Overall, the results suggest the application of tert-Ser-PTX as a robust antitumor/antimetastatic treatment for PCa.
Collapse
Affiliation(s)
- Yolanda Fernández
- Functional Validation & Preclinical Research (FVPR) CIBBIM‐Nanomedicine Vall d'Hebron Institut de Recerca (VHIR) Universitat Autònoma de Barcelona (UAB) Barcelona 08035 Spain
- Drug Delivery & Targeting Group CIBBIM‐Nanomedicine Vall d'Hebron Institut de Recerca (VHIR) Universitat Autònoma de Barcelona (UAB) Barcelona 08035 Spain
- Networking Research Center on Bioengineering Biomaterials and Nanomedicine (CIBER‐BBN) Barcelona 08035 Spain
| | - Julie Movellan
- Polymer Therapeutics Laboratory. Centro de Investigación Príncipe Felipe. Av. Eduardo Primo Yúfera 3 Valencia 46012 Spain
| | - Laia Foradada
- Functional Validation & Preclinical Research (FVPR) CIBBIM‐Nanomedicine Vall d'Hebron Institut de Recerca (VHIR) Universitat Autònoma de Barcelona (UAB) Barcelona 08035 Spain
- Drug Delivery & Targeting Group CIBBIM‐Nanomedicine Vall d'Hebron Institut de Recerca (VHIR) Universitat Autònoma de Barcelona (UAB) Barcelona 08035 Spain
- Networking Research Center on Bioengineering Biomaterials and Nanomedicine (CIBER‐BBN) Barcelona 08035 Spain
| | - Vanessa Giménez
- Polymer Therapeutics Laboratory. Centro de Investigación Príncipe Felipe. Av. Eduardo Primo Yúfera 3 Valencia 46012 Spain
| | - Natalia García‐Aranda
- Functional Validation & Preclinical Research (FVPR) CIBBIM‐Nanomedicine Vall d'Hebron Institut de Recerca (VHIR) Universitat Autònoma de Barcelona (UAB) Barcelona 08035 Spain
- Drug Delivery & Targeting Group CIBBIM‐Nanomedicine Vall d'Hebron Institut de Recerca (VHIR) Universitat Autònoma de Barcelona (UAB) Barcelona 08035 Spain
- Networking Research Center on Bioengineering Biomaterials and Nanomedicine (CIBER‐BBN) Barcelona 08035 Spain
| | - Sandra Mancilla
- Functional Validation & Preclinical Research (FVPR) CIBBIM‐Nanomedicine Vall d'Hebron Institut de Recerca (VHIR) Universitat Autònoma de Barcelona (UAB) Barcelona 08035 Spain
- Drug Delivery & Targeting Group CIBBIM‐Nanomedicine Vall d'Hebron Institut de Recerca (VHIR) Universitat Autònoma de Barcelona (UAB) Barcelona 08035 Spain
- Networking Research Center on Bioengineering Biomaterials and Nanomedicine (CIBER‐BBN) Barcelona 08035 Spain
| | - Ana Armiñán
- Polymer Therapeutics Laboratory. Centro de Investigación Príncipe Felipe. Av. Eduardo Primo Yúfera 3 Valencia 46012 Spain
| | - Sven Even Borgos
- Department of Biotechnology and Nanomedicine SINTEF Industry Trondheim NO‐7465 Norway
| | - Astrid Hyldbakk
- Department of Biotechnology and Nanomedicine SINTEF Industry Trondheim NO‐7465 Norway
| | - Anna Bogdanska
- Laboratory for Biological Characterization of Advanced Materials (LBCAM) Trinity Translational Medicine Institute Trinity College Dublin Dublin D08 W9RT Ireland
- Trinity St James's Cancer Institute Trinity College Dublin the University of Dublin Dublin D08 W9RT Ireland
| | - Oliviero L. Gobbo
- Trinity St James's Cancer Institute Trinity College Dublin the University of Dublin Dublin D08 W9RT Ireland
- School of Pharmacy and Pharmaceutical Sciences Trinity College Dublin Dublin D02 R590 Ireland
| | - Adriele Prina‐Mello
- Laboratory for Biological Characterization of Advanced Materials (LBCAM) Trinity Translational Medicine Institute Trinity College Dublin Dublin D08 W9RT Ireland
- Trinity St James's Cancer Institute Trinity College Dublin the University of Dublin Dublin D08 W9RT Ireland
| | - Jessica Ponti
- European Commission Joint Research Centre (JRC) via Fermi 2749 Ispra 21027 Italy
| | - Luigi Calzolai
- European Commission Joint Research Centre (JRC) via Fermi 2749 Ispra 21027 Italy
| | - Oleksandr Zagorodko
- Polymer Therapeutics Laboratory. Centro de Investigación Príncipe Felipe. Av. Eduardo Primo Yúfera 3 Valencia 46012 Spain
| | - Elena Gallon
- Polymer Therapeutics Laboratory. Centro de Investigación Príncipe Felipe. Av. Eduardo Primo Yúfera 3 Valencia 46012 Spain
| | - Amaya Niño‐Pariente
- Polymer Therapeutics Laboratory. Centro de Investigación Príncipe Felipe. Av. Eduardo Primo Yúfera 3 Valencia 46012 Spain
| | - Alison Paul
- School of Chemistry Cardiff University Main Building, Park Place Cardiff CF10 3AT UK
| | - Simó Schwartz Jr
- Drug Delivery & Targeting Group CIBBIM‐Nanomedicine Vall d'Hebron Institut de Recerca (VHIR) Universitat Autònoma de Barcelona (UAB) Barcelona 08035 Spain
- Networking Research Center on Bioengineering Biomaterials and Nanomedicine (CIBER‐BBN) Barcelona 08035 Spain
| | - Ibane Abasolo
- Functional Validation & Preclinical Research (FVPR) CIBBIM‐Nanomedicine Vall d'Hebron Institut de Recerca (VHIR) Universitat Autònoma de Barcelona (UAB) Barcelona 08035 Spain
- Drug Delivery & Targeting Group CIBBIM‐Nanomedicine Vall d'Hebron Institut de Recerca (VHIR) Universitat Autònoma de Barcelona (UAB) Barcelona 08035 Spain
- Networking Research Center on Bioengineering Biomaterials and Nanomedicine (CIBER‐BBN) Barcelona 08035 Spain
| | - María J. Vicent
- Polymer Therapeutics Laboratory. Centro de Investigación Príncipe Felipe. Av. Eduardo Primo Yúfera 3 Valencia 46012 Spain
| |
Collapse
|
4
|
Affiliation(s)
- Adrián Badía
- POLYMAT, University of the Basque Country UPV-EHU, Kimika Aplikatua Saila, Joxe Mari Korta Zentroa, Tolosa Hiribidea 72, 20018 Donostia-San Sebastian, Spain
| | - Julie Movellan
- POLYMAT, University of the Basque Country UPV-EHU, Kimika Aplikatua Saila, Joxe Mari Korta Zentroa, Tolosa Hiribidea 72, 20018 Donostia-San Sebastian, Spain
| | - María Jesús Barandiaran
- POLYMAT, University of the Basque Country UPV-EHU, Kimika Aplikatua Saila, Joxe Mari Korta Zentroa, Tolosa Hiribidea 72, 20018 Donostia-San Sebastian, Spain
| | - Jose Ramon Leiza
- POLYMAT, University of the Basque Country UPV-EHU, Kimika Aplikatua Saila, Joxe Mari Korta Zentroa, Tolosa Hiribidea 72, 20018 Donostia-San Sebastian, Spain
| |
Collapse
|
5
|
Plyduang T, Armiñán A, Movellan J, England RM, Wiwattanapatapee R, Vicent MJ. Polyacetal-Based Combination Therapy for the Treatment of Prostate Cancer. Macromol Rapid Commun 2018; 39:e1800265. [DOI: 10.1002/marc.201800265] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2018] [Revised: 06/11/2018] [Indexed: 12/20/2022]
Affiliation(s)
- Thipapun Plyduang
- Department of Pharmaceutical Technology; Faculty of Pharmaceutical Sciences; Prince of Songkla University; Hat Yai Songkla 90112 Thailand
- School of Pharmacy; Walailak University; Thasala Nakhon Si Thammarat 80161 Thailand
| | - Ana Armiñán
- Polymer Therapeutics Laboratory; Centro de Investigación Príncipe Felipe; Av Eduardo Primo Yúfera 3 46012 Valencia Spain
| | - Julie Movellan
- Polymer Therapeutics Laboratory; Centro de Investigación Príncipe Felipe; Av Eduardo Primo Yúfera 3 46012 Valencia Spain
| | - Richard M. England
- Polymer Therapeutics Laboratory; Centro de Investigación Príncipe Felipe; Av Eduardo Primo Yúfera 3 46012 Valencia Spain
| | - Ruedeekorn Wiwattanapatapee
- Department of Pharmaceutical Technology; Faculty of Pharmaceutical Sciences; Prince of Songkla University; Hat Yai Songkla 90112 Thailand
| | - María J. Vicent
- Polymer Therapeutics Laboratory; Centro de Investigación Príncipe Felipe; Av Eduardo Primo Yúfera 3 46012 Valencia Spain
| |
Collapse
|
6
|
Armiñán A, Mendes L, Carrola J, Movellan J, Vicent MJ, Duarte IF. HIF-1α inhibition by diethylstilbestrol and its polyacetal conjugate in hypoxic prostate tumour cells: insights from NMR metabolomics. J Drug Target 2017; 25:845-855. [PMID: 28737429 DOI: 10.1080/1061186x.2017.1358728] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
In this study, we have employed 1H NMR metabolomics to assess the metabolic responses of PC3 prostate tumour cells to hypoxia and to pharmacological HIF-1α inhibition by DES or its polyacetal conjugate tert-DES. Oxygen deprivation prompted a number of changes in intracellular composition and metabolic activity, mainly reflecting upregulated glycolysis, amino acid catabolism and other compensatory mechanisms used by hypoxic cells to deal with oxidative imbalance and energy deficit. Cell treatment with a non-cytotoxic concentration of DES, under hypoxia, triggered significant changes in 17 metabolites. Among these, lactate, phosphocreatine and reduced glutathione, whose levels showed opposite variations in hypoxic and drug-treated cells, emerged as possible markers of DES-induced HIF-1α inhibition. Furthermore, the free drug had a much higher impact on the cellular metabolome than tert-DES, particularly concerning polyamine and pyrimidine biosynthetic pathways, known to be tightly involved in cell proliferation and growth. This is likely due to the different cell pharmacokinetics observed between free and conjugated DES. Overall, this study has revealed a number of unanticipated metabolic changes that inform on DES and tert-DES direct cellular effects, providing further insight into their mode of action at the biochemical level.
Collapse
Affiliation(s)
- Ana Armiñán
- a Polymer Therapeutics Lab , Centro de Investigación Príncipe Felipe (CIPF) , Valencia , Spain
| | - Luís Mendes
- b Department of Chemistry, CICECO - Aveiro Institute of Materials , University of Aveiro , Aveiro , Portugal
| | - Joana Carrola
- b Department of Chemistry, CICECO - Aveiro Institute of Materials , University of Aveiro , Aveiro , Portugal
| | - Julie Movellan
- a Polymer Therapeutics Lab , Centro de Investigación Príncipe Felipe (CIPF) , Valencia , Spain
| | - María J Vicent
- a Polymer Therapeutics Lab , Centro de Investigación Príncipe Felipe (CIPF) , Valencia , Spain
| | - Iola F Duarte
- b Department of Chemistry, CICECO - Aveiro Institute of Materials , University of Aveiro , Aveiro , Portugal
| |
Collapse
|
7
|
Kiew LV, Cheah HY, Voon SH, Gallon E, Movellan J, Ng KH, Alpugan S, Lee HB, Dumoulin F, Vicent MJ, Chung LY. Near-infrared activatable phthalocyanine-poly-L-glutamic acid conjugate: increased cellular uptake and light–dark toxicity ratio toward an effective photodynamic cancer therapy. Nanomedicine: Nanotechnology, Biology and Medicine 2017; 13:1447-1458. [DOI: 10.1016/j.nano.2017.02.002] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/14/2016] [Revised: 12/23/2016] [Accepted: 02/05/2017] [Indexed: 12/31/2022]
|
8
|
Moreno J, Ramos-Castro J, Movellan J, Parrado E, Rodas G, Capdevila L. Facial Video-Based Photoplethysmography to Detect HRV at Rest. Int J Sports Med 2015; 36:474-80. [DOI: 10.1055/s-0034-1398530] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- J. Moreno
- Laboratory of Sport Psychology, Universitat Autònoma de Barcelona, Bellaterra, Spain
| | - J. Ramos-Castro
- Electronic Engineering Department, Universitat Politècnica de Catalunya, Barcelona, Spain
| | | | - E. Parrado
- Laboratory of Sport Psychology, Universitat Autònoma de Barcelona, Bellaterra, Spain
| | - G. Rodas
- Medical Services F.C. Barcelona, F.C. Barcelona, Barcelona, Spain
| | - L. Capdevila
- Laboratory of Sport Psychology, Universitat Autònoma de Barcelona, Bellaterra, Spain
| |
Collapse
|
9
|
Movellan J, González-Pastor R, Martín-Duque P, Sierra T, de la Fuente JM, Serrano JL. New Ionic bis-MPA and PAMAM Dendrimers: A Study of Their Biocompatibility and DNA-Complexation. Macromol Biosci 2015; 15:657-67. [DOI: 10.1002/mabi.201400422] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2014] [Revised: 11/21/2014] [Indexed: 01/19/2023]
Affiliation(s)
- Julie Movellan
- Departamento de Química Orgánica-Instituto de Nanociencia de Aragón (INA); University of Zaragoza; C/Pedro Cerbuna 12 50009 Zaragoza Spain
| | - Rebeca González-Pastor
- Gene and Cell Therapy Group; Institute of Health Sciences of Aragon-IIS Aragon; 50009 Zaragoza Spain
| | - Pilar Martín-Duque
- Gene and Cell Therapy Group; Institute of Health Sciences of Aragon-IIS Aragon; 50009 Zaragoza Spain
- Fundación Agencia Aragonesa para la Investigación y el Desarollo (ARAID); C/María de Luna, no 11, Edificio CEEI Aragón 50018 Zaragoza Spain
- Biotechnology Department; University Francisco de Vitoria; Madrid 28223 Spain
| | - Teresa Sierra
- Instituto de Ciencia de Materiales de Aragón (ICMA); University of Zaragoza-CSIC; Calle Pedro Cerbuna 12 50009 Zaragoza Spain
| | - Jesús M. de la Fuente
- Instituto de Nanociencia de Aragón-INA; C/Mariano Esquillor Edificio I+D 50018 Zaragoza Spain
- Fundación Agencia Aragonesa para la Investigación y el Desarollo (ARAID); C/María de Luna, no 11, Edificio CEEI Aragón 50018 Zaragoza Spain
| | - José Luis Serrano
- Departamento de Química Orgánica-Instituto de Nanociencia de Aragón (INA); University of Zaragoza; C/Pedro Cerbuna 12 50009 Zaragoza Spain
| |
Collapse
|
10
|
Abstract
Branched polymers own special properties derived from their intrinsic characteristics. These properties make them ideal candidates to be used as carriers for an improved generation of polymer-drug conjugates.
Collapse
Affiliation(s)
- A. Duro-Castano
- Centro de Investigación Príncipe Felipe
- Polymer Therapeutics Lab
- E-46012 Valencia
- Spain
| | - J. Movellan
- Centro de Investigación Príncipe Felipe
- Polymer Therapeutics Lab
- E-46012 Valencia
- Spain
| | - M. J. Vicent
- Centro de Investigación Príncipe Felipe
- Polymer Therapeutics Lab
- E-46012 Valencia
- Spain
| |
Collapse
|
11
|
Movellan J, Urbán P, Moles E, de la Fuente JM, Sierra T, Serrano JL, Fernàndez-Busquets X. Amphiphilic dendritic derivatives as nanocarriers for the targeted delivery of antimalarial drugs. Biomaterials 2014; 35:7940-50. [PMID: 24930847 DOI: 10.1016/j.biomaterials.2014.05.061] [Citation(s) in RCA: 64] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2014] [Accepted: 05/21/2014] [Indexed: 12/21/2022]
Abstract
It can be foreseen that in a future scenario of malaria eradication, a varied armamentarium will be required, including strategies for the targeted administration of antimalarial compounds. The development of nanovectors capable of encapsulating drugs and of delivering them to Plasmodium-infected cells with high specificity and efficacy and at an affordable cost is of particular interest. With this objective, dendritic derivatives based on 2,2-bis(hydroxymethyl)propionic acid (bis-MPA) and Pluronic(®) polymers have been herein explored. Four different dendritic derivatives have been tested for their capacity to encapsulate the antimalarial drugs chloroquine (CQ) and primaquine (PQ), their specific targeting to Plasmodium-infected red blood cells (pRBCs), and their antimalarial activity in vitro against the human pathogen Plasmodium falciparum and in vivo against the rodent malaria species Plasmodium yoelii. The results obtained have allowed the identification of two dendritic derivatives exhibiting specific targeting to pRBCs vs. non-infected RBCs, which reduce the in vitro IC50 of CQ and PQ by ca. 3- and 4-fold down to 4.0 nm and 1.1 μm, respectively. This work on the application of dendritic derivatives to antimalarial targeted drug delivery opens the way for the use of this new type of chemicals in future malaria eradication programs.
Collapse
Affiliation(s)
- Julie Movellan
- Departamento de Química Orgánica-Institute of Nanoscience of Aragon (INA), University of Zaragoza, Pedro Cerbuna 12, ES-50009 Zaragoza, Spain
| | - Patricia Urbán
- Nanomalaria Group, Institute for Bioengineering of Catalonia (IBEC), Baldiri Reixac 10-12, ES-08028 Barcelona, Spain; Barcelona Centre for International Health Research (CRESIB, Hospital Clínic-Universitat de Barcelona), Rosselló 149-153, ES-08036 Barcelona, Spain
| | - Ernest Moles
- Nanomalaria Group, Institute for Bioengineering of Catalonia (IBEC), Baldiri Reixac 10-12, ES-08028 Barcelona, Spain; Barcelona Centre for International Health Research (CRESIB, Hospital Clínic-Universitat de Barcelona), Rosselló 149-153, ES-08036 Barcelona, Spain
| | - Jesús M de la Fuente
- Fundación Agencia Aragonesa para la Investigación y el Desarollo (ARAID), María de Luna 11, 1ª planta, Edificio CEEI Aragón, ES-50018 Zaragoza, Spain; Institute of Nanoscience of Aragon (INA), University of Zaragoza, Mariano Esquillor, Edificio I+D, ES-50018 Zaragoza, Spain
| | - Teresa Sierra
- Instituto de Ciencia de Materiales de Aragón (ICMA), University of Zaragoza-CSIC, Pedro Cerbuna 12, ES-50009 Zaragoza, Spain
| | - José Luis Serrano
- Departamento de Química Orgánica-Institute of Nanoscience of Aragon (INA), University of Zaragoza, Pedro Cerbuna 12, ES-50009 Zaragoza, Spain.
| | - Xavier Fernàndez-Busquets
- Nanomalaria Group, Institute for Bioengineering of Catalonia (IBEC), Baldiri Reixac 10-12, ES-08028 Barcelona, Spain; Barcelona Centre for International Health Research (CRESIB, Hospital Clínic-Universitat de Barcelona), Rosselló 149-153, ES-08036 Barcelona, Spain.
| |
Collapse
|
12
|
Movellan J, Rocher F, Chikh Z, Marivingt-Mounir C, Bonnemain JL, Chollet JF. Synthesis and evaluation as biodegradable herbicides of halogenated analogs of L-meta-tyrosine. Environ Sci Pollut Res Int 2014; 21:4861-70. [PMID: 23224500 DOI: 10.1007/s11356-012-1302-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/27/2012] [Accepted: 11/05/2012] [Indexed: 06/01/2023]
Abstract
L-meta-tyrosine is an herbicidal nonprotein amino acid isolated some years ago from fine fescue grasses and characterized by its almost immediate microbial degradation in soil (half-life <24 h). Nine monohalogenated or dihalogenated analogs of this allelochemical have been obtained through a seven-step stereoselective synthesis from commercial halogenated phenols. Bioassays showed a large range of biological responses, from a growth root inhibition of lettuce seedling similar to that noted with m-tyrosine [2-amino-3-(2-chloro-5-hydroxyphenyl)propanoic acid or compound 8b] to an increase of the primary root growth concomitant with a delay of secondary root initiation [2-amino-3-[2-fluoro-5-hydroxy-3-(trifluoromethyl)phenyl]propanoic acid or compound 8h]. Compound 8b was slightly less degraded than m-tyrosine in the nonsterilized nutritive solution used for lettuce development, while the concentration of compound 8h remained unchanged for at least 2 weeks. These data indicate that it is possible to manipulate both biological properties and degradation of m-tyrosine by halogen addition.
Collapse
Affiliation(s)
- Julie Movellan
- Institut de Chimie des Milieux et des Matériaux de Poitiers, Unité Mixte de Recherche CNRS 7285, Université de Poitiers, 40 Avenue du Recteur Pineau, 86022, Poitiers Cedex, France
| | | | | | | | | | | |
Collapse
|
13
|
Talbott W, Huang H, Movellan J. Continuous Time Infomax Models of Oculomotor Control. J Vis 2012. [DOI: 10.1167/12.9.1019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
14
|
Abstract
Neuropsychological and neuroimaging evidence suggests that the human brain contains facial expression recognition detectors specialized for specific discrete emotions. However, some human behavioral data suggest that humans recognize expressions as similar and not discrete entities. This latter observation has been taken to indicate that internal representations of facial expressions may be best characterized as varying along continuous underlying dimensions. To examine the potential compatibility of these two views, the present study compared human and support vector machine (SVM) facial expression recognition performance. Separate SVMs were trained to develop fully automatic optimal recognition of one of six basic emotional expressions in real-time with no explicit training on expression similarity. Performance revealed high recognition accuracy for expression prototypes. Without explicit training of similarity detection, magnitude of activation across each emotion-specific SVM captured human judgments of expression similarity. This evidence suggests that combinations of expert classifiers from separate internal neural representations result in similarity judgments between expressions, supporting the appearance of a continuous underlying dimensionality. Further, these data suggest similarity in expression meaning is supported by superficial similarities in expression appearance.
Collapse
Affiliation(s)
- J M Susskind
- Department of Psychology, University of Toronto, Canada
| | | | | | | | | |
Collapse
|